MedTrace Logo

Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers

NCT02442310 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-05-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to look at the pharmacokinetics of a new formulation of deferiprone (deferiprone delayed release tablets) under fed and fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Deferiprone delayed release tablet formulation

Deferiprone 600 mg delayed release tablet formulation

DRUG

Deferiprone oral solution

Deferiprone 100 mg/mL oral solution

Sponsors & Collaborators

  • Algorithme Pharma Inc

    collaborator INDUSTRY

  • ApoPharma

    lead INDUSTRY

Principal Investigators

  • Fernando Tricta, MD · ApoPharma Inc.

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02442310 on ClinicalTrials.gov